Last reviewed · How we verify

Aprepitant plus Ondansetron

University of Pittsburgh · FDA-approved active Small molecule

Aprepitant blocks neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone while ondansetron blocks serotonin 5-HT3 receptors, together providing dual antiemetic coverage against chemotherapy-induced nausea and vomiting.

Aprepitant blocks neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone while ondansetron blocks serotonin 5-HT3 receptors, together providing dual antiemetic coverage against chemotherapy-induced nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy, Postoperative nausea and vomiting (PONV) prevention.

At a glance

Generic nameAprepitant plus Ondansetron
Also known asEmend
SponsorUniversity of Pittsburgh
Drug classNK1 receptor antagonist + 5-HT3 receptor antagonist combination
TargetNK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
ModalitySmall molecule
Therapeutic areaOncology / Gastroenterology
PhaseFDA-approved

Mechanism of action

Aprepitant is a selective antagonist of human substance P/neurokinin-1 receptors, which are involved in the central control of emesis, particularly delayed nausea and vomiting. Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. The combination targets complementary pathways to provide broader and more effective antiemetic coverage than either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results